-
Mitsubishi Tanabe Pharma America Announces Publication of Three-Year Outcomes from Phase 2b BeyoND Study of Investigational ND0612 in Parkinson’s Disease
-
Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Disease Progression with RADICAVA® (edaravone) in ALS
-
Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS
-
Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612 at the 2024 Annual Meeting of the Parkinson Study Group
-
Mitsubishi Tanabe Pharma America to Present New ALS Research at MNDA’s 35th International Symposium on ALS/MND
-
Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA ORS® (edaravone) from a Phase 3b Efficacy and Safety Extension Study and a Clinical Analysis of Multiple Studies at NEALS 2024
-
Mitsubishi Tanabe Pharma America Unveils New ALS Research Findings at NEALS 2024 Annual Meeting
-
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2024 AANEM Annual Meeting
-
Mitsubishi Tanabe Pharma America to Showcase New RADICAVA ORS® (edaravone) Real-World Data at 2024 Academy of Managed Care Pharmacy Nexus Meeting
-
Mitsubishi Tanabe Pharma America to Discontinue Intravenous (IV) RADICAVA® (edaravone)